Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,374 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,072 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04718701 | Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer(ATNPA) | unknown | Phase 2 | 53 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04994236 | Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy | unknown | Phase 2 | 49 | Hui-Chuan SunOTHER | 1 | Aug 13, 2021 |
| clinicaltrials |
| NCT04890392 | Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC | unknown | Phase 2 | 20 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT04996446 | ALPPS Combined With Tislelizumab in Liver Malignancy | unknown | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT03528785 | A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer(nITRo) | unknown | Phase 2 | 67 | Centro Ricerche Cliniche di VeronaOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT04973475 | Indocyanine Green Tracer Using in Laparoscopic Distal Gastrectomy for Early Gastric Cancer | unknown | Phase 2 | 180 | Fujian Medical UniversityOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT04961918 | The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT01676259 | A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer(PROTACT) | unknown | Phase 2 | 80 | Silenseed LtdINDUSTRY | 2 | Jul 2, 2021 | clinicaltrials |
| NCT04806243 | Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020） | unknown | Phase 2 | 69 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 30, 2021 | clinicaltrials |
| NCT04926532 | Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma(Toripalimab) | unknown | Phase 1 / Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT04913480 | SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 37 | The University of Hong KongOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04909866 | The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study | unknown | Phase 2 / Phase 3 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04781686 | Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer | unknown | Phase 2 | 35 | Zhou FuxiangOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT04814030 | Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial(AIPD-1) | unknown | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2021 | clinicaltrials |
| NCT03971201 | A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion | unknown | Phase 2 | 200 | White Plains HospitalOTHER | 1 | Apr 14, 2021 | clinicaltrials |
| NCT04843943 | Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 0 | Apr 14, 2021 | clinicaltrials |
| NCT04442984 | FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)(IRIGA) | unknown | Phase 2 | 326 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT04834986 | Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT04826406 | A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs). | unknown | Phase 2 | 40 | Hunan Cancer HospitalOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04167293 | Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01)(ISBRT01) | unknown | Phase 2 / Phase 3 | 116 | Mian XIOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT04042805 | Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 36 | Baocai XingOTHER | 1 | Mar 2, 2021 | clinicaltrials |
| NCT04170179 | Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT04741165 | Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 72 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03941626 | Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies | unknown | Phase 1 / Phase 2 | 50 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT03794440 | A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma. | unknown | Phase 2 / Phase 3 | 595 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jan 22, 2021 | clinicaltrials |
| NCT04479527 | Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 34 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 14, 2021 | clinicaltrials |
| NCT04183088 | Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 125 | National Taiwan University HospitalOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT04652492 | Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 72 | Zhongda HospitalOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT04627363 | HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 0 | Nov 13, 2020 | clinicaltrials |
| NCT04621370 | A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer(PRIME-RT) | unknown | Phase 2 | 48 | Liz-Anne LewsleyOTHER | 0 | Nov 9, 2020 | clinicaltrials |
| NCT04317248 | "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma | unknown | Phase 2 | 600 | Yuehua HuangOTHER | 1 | Oct 29, 2020 | clinicaltrials |
| NCT03645980 | DKN-01 Inhibition in Advanced Liver Cancer | unknown | Phase 1 / Phase 2 | 70 | Johannes Gutenberg University MainzOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT04597970 | TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC(OXRI) | unknown | Phase 2 | 66 | Peking University Cancer Hospital & InstituteOTHER | 0 | Oct 22, 2020 | clinicaltrials |
| NCT04454762 | A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function(CaboCHILD) | unknown | Phase 2 | 20 | Johannes Gutenberg University MainzOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT04538313 | A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs | unknown | Phase 1 / Phase 2 | 40 | CAR-T (Shanghai) Cell Biotechnology Co., Ltd.NETWORK | 1 | Sep 4, 2020 | clinicaltrials |
| NCT04523662 | Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer | unknown | Phase 2 | 27 | Beijing Tsinghua Chang Gung HospitalOTHER | 0 | Aug 21, 2020 | clinicaltrials |
| NCT04297202 | SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma(HCC-009) | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 7, 2020 | clinicaltrials |
| NCT04503967 | Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer(OASIS) | unknown | Phase 2 | 48 | Shanghai Zhongshan HospitalOTHER | 0 | Aug 7, 2020 | clinicaltrials |
| NCT03642561 | Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE | unknown | Phase 2 / Phase 3 | 300 | Fudan UniversityOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT04475159 | Combined Neoadjuvant Systemic and PIPAC Therapy (NASPIT) for Patients With Colorectal Peritoneal Metastasis Eligible for CRS and HIPEC: A Prospective Phase II Trial | unknown | Phase 2 | 50 | Prof. Aviram NissanOTHER_GOV | 0 | Jul 17, 2020 | clinicaltrials |
| NCT04216758 | Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer | unknown | Phase 2 | 300 | Fudan UniversityOTHER | 1 | Jun 30, 2020 | clinicaltrials |
| NCT04411706 | A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 46 | Xin-Hua XuOTHER | 1 | Jun 24, 2020 | clinicaltrials |
| NCT04435977 | Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma(Immunocabo) | unknown | Phase 2 | 46 | Istituto Clinico HumanitasOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04380103 | A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 106 | Chinese Academy of Medical SciencesOTHER | 1 | May 8, 2020 | clinicaltrials |
| NCT03592706 | Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy | unknown | Phase 2 / Phase 3 | 60 | Ivy Life Sciences, Co., LtdINDUSTRY | 1 | Apr 16, 2020 | clinicaltrials |
| NCT04080154 | Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma(ALTER-H-002) | unknown | Phase 2 | 28 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT02161822 | Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients | unknown | Phase 2 | 60 | Samsung Medical CenterOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT04319484 | Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus(LLTHVV) | unknown | Phase 2 / Phase 3 | 108 | RenJi HospitalOTHER | 0 | Mar 24, 2020 | clinicaltrials |
| NCT04273100 | PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC(PLTHCC) | unknown | Phase 2 | 56 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT04263870 | Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction(CTSCAPOXSEA) | unknown | Phase 2 | 36 | Sichuan UniversityOTHER | 1 | Feb 11, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 16, 2021source: clinicaltrials